Plain-English translation of NCT07189871 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called , which is a radioactive antibody designed to find and attack cancer cells in people whose cancers have stopped responding to standard treatments. The medication works by targeting a specific protein on cancer cells and delivering radiation directly to them. Researchers want to find the right dose and learn how well this treatment works for various types of advanced cancers.
Many patients with advanced cancers like prostate, lung, breast, and ovarian cancer eventually stop responding to their current treatments. This medication represents a new approach that may help patients whose options have become limited, by using radioactive targeting to attack cancer cells more directly.
You likely qualify if…
You likely don't qualify if…
The trial has two main phases: first, researchers will gradually increase doses of the medication to find the safest and most effective dose, and then expand to more patients at that dose level. During treatment, you will receive injections of the medication and undergo imaging scans to track how your cancer responds and how the medication moves through your body. You will have screening visits, treatment visits, and long-term follow-up appointments to monitor your safety and how well the treatment is working.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States